

Title (en)
USE OF MULLERIAN INHIBITING SUBSTANCE FOR TREATING TUMORS AND FOR MODULATING CLASS 1 MAJOR HISTOCOMPATIBILITY ANTIGEN EXPRESSION.

Title (de)
VERWENDUNG VON MÜLLERSCHER INHIBIERENDER SUBSTANZ ZUR BEHANDLUNG VON TUMOREN UND ZUR MODULATION DER EXPRESSION VON KLASSE 1-HAUPTHISTOKOMPATIBILITÄTSANTIGEN.

Title (fr)
HORMONE ANTIMULLERIEENNE UTILISEE POUR LE TRAITEMENT DE TUMEURS ET LA MODULATION DE L'EXPRESSION DE L'ANTIGENE D'HISTOCOMPATIBILITE MAJEURE CLASSE I.

Publication
EP 0646010 A4 19970423 (EN)

Application
EP 93916585 A 19930618

Priority

- US 9305791 W 19930618
- US 90163792 A 19920619
- US 712593 A 19930121

Abstract (en)
[origin: WO9400133A1] This application concerns the treatment of certain tumors using an effective amount of the glycoprotein Muellerian Inhibiting Substance (MIS). This application further concerns the treatment of certain tumors using an effective amount of the C-terminal fragment of MIS. Also, this application concerns DNA sequences encoding the C-terminal fragment of MIS, vectors containing the DNA sequence and transformed host cells capable of producing the C-terminal fragment. This application further concerns treating certain tumors by transfecting tumor cells with a gene coding for MIS or the C-terminal fragment of MIS. Gene therapy treatments for inhibiting growth of certain tumors are also provided. Further, this application concerns a method for modulating class I histocompatibility antigens with MIS and EGF.

IPC 1-7
A61K 31/70; A61K 38/00; C07K 1/00; C07K 15/14; C12N 1/19; C12N 1/21; C12N 5/10; C12N 15/09; C12N 15/10; C12N 15/16

IPC 8 full level
C07K 14/575 (2006.01); **C07K 16/26** (2006.01); **A61K 38/00** (2006.01); **A61K 48/00** (2006.01)

CPC (source: EP)
C07K 14/575 (2013.01); **C07K 16/26** (2013.01); **A61K 38/00** (2013.01); **A61K 48/00** (2013.01)

Citation (search report)

- [Y] WO 9207943 A1 19920514 - SOMATIX THERAPY CORP [US], et al
- [AD] US 5011687 A 19910430 - DONAHOE PATRICIA K [US], et al
- [XDY] CATE R.L. ET AL.: "Isolation of the bovine and human genes for Müllerian Inhibiting Substance and expression of the human gene in animal cells.", CELL, vol. 45, June 1986 (1986-06-01), pages 685 - 698, XP002024939
- [YD] PEPINSKY R.B. ET AL.: "Proteolytic processing of Mullerian Inhibiting Substance produces a transforming growth factor-beta-like fragment.", J.BIOL.CHEM., vol. 263, no. 35, 1988, pages 18961 - 18964, XP002024938
- [PX] RAGIN R.C.: "Human Mullerian Inhibiting Substance: Enhanced purification imparts biochemical stability and restores antiproliferation effect.", PROTEIN EXPRESSION AND PURIFICATION, vol. 3, no. 3, 22 June 1992 (1992-06-22), pages 236 - 245, XP000644388
- [PX] MACLAUGHLIN D.T.: "Mullerian duct regression and antiproliferative bioactivities of Mullerian Inhibiting Substance reside in its carboxy-terminal domain.", ENDOCRINOLOGY, vol. 131, no. 1, July 1992 (1992-07-01), pages 291 - 296, XP000644378

Citation (examination)

- KASID A. ET AL: PNAS, 1990, vol. 87, pages 473-477, 'Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man'
- TEIXEIRA J. ET AL: "Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level", ENDOCRINOLOGY, vol. 140, no. 10, October 1999 (1999-10-01), pages 4732 - 4738
- SEGEV D.L. ET AL: "Müllerian inhibiting substance regulates NFkB signaling and growth of mammary epithelial cells in vivo", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 29, 20 July 2001 (2001-07-20), pages 26799 - 26806
- SEGEV D.L. ET AL: "Müllerian inhibiting substance inhibits breast cancer cell growth through an NFkB-mediated pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 37, 15 September 2000 (2000-09-15), pages 28371 - 28379, XP002382653, DOI: doi:10.1074/jbc.M004554200
- See also references of WO 9400133A1

Designated contracting state (EPC)
CH DE DK ES FR GB IE IT LI NL PT SE

DOCDB simple family (publication)
WO 9400133 A1 19940106; EP 0646010 A1 19950405; EP 0646010 A4 19970423

DOCDB simple family (application)
US 9305791 W 19930618; EP 93916585 A 19930618